Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.06.2009 | Epidemiology

Vitamin D receptor variants and breast cancer risk in the Polish population

verfasst von: P. Gapska, R. J. Scott, P. Serrano-Fernandez, T. Huzarski, T. Byrski, J. Kładny, J. Gronwald, B. Górski, C. Cybulski, J. Lubinski, T. Dębniak

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to determine whether four VDR gene single nucleotide polymorphisms (SNPs: rs1544410, rs731236, rs10735810 and rs4516035) are associated with breast cancer risk in Polish population. Two independent series of female patients were employed: 960 consecutive breast cancer cases, and 800 unselected early onset cases diagnosed under the age of 51. The control group for the consecutive breast cancer cases consisted of 960 healthy, age-matched women with a negative cancer family history. 550 healthy women, aged 51 or less, with negative cancer family history were selected as the independent controls for the early onset breast cancer cases. The frequencies of the VDR polymorphisms in the unselected cases when compared to the respective control population failed to reveal any association between the individual SNPs and disease. Examination of the group of early-onset patients, revealed an association between rs10735810 and increased breast cancer risk. Heterozygous carriers for the change had an OR = 1.73 (95% CI 1.33–2.26, P < 0.0001) and homozygous carriers OR = 2.34 (95% CI 1.71–3.21, P < 0.0001). The remaining three examined SNPs failed to show any association with disease risk. In summary, this study has identified an association between the VDR gene and early onset breast cancer risk in the Polish population.
Literatur
2.
Zurück zum Zitat Trabert B, Malone KE, Daling JR et al (2007) Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African–American women. Breast Cancer Res 9(6):R84. doi:10.1186/bcr1833 PubMedCrossRef Trabert B, Malone KE, Daling JR et al (2007) Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African–American women. Breast Cancer Res 9(6):R84. doi:10.​1186/​bcr1833 PubMedCrossRef
5.
Zurück zum Zitat Gross C, Ecceleshall TR, Malloy PJ et al (1996) The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 11:1850–1855PubMedCrossRef Gross C, Ecceleshall TR, Malloy PJ et al (1996) The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 11:1850–1855PubMedCrossRef
7.
Zurück zum Zitat Saijo T, Naito E, Ito M et al (1991) Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 22:166–167PubMedCrossRef Saijo T, Naito E, Ito M et al (1991) Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 22:166–167PubMedCrossRef
8.
Zurück zum Zitat Schurzenbecker L, Scardaville B, Kratzeisen C et al (1994) Isolation and analysis of cDNA encoding a naturally occurring truncated form of the human vitamin D receptor. In: Bouilon R, Norman A, Thomasset M (eds) Vitamin D: a pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp 253–257 Schurzenbecker L, Scardaville B, Kratzeisen C et al (1994) Isolation and analysis of cDNA encoding a naturally occurring truncated form of the human vitamin D receptor. In: Bouilon R, Norman A, Thomasset M (eds) Vitamin D: a pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp 253–257
9.
Zurück zum Zitat Scott CM, Narasimha S, WenRong X, Rahul R (2001) Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1α, 25-dihydroxyvitamin D3 receptor? Steroid 66:189–2001. doi:10.1016/S0039-128X(00)00134-3 CrossRef Scott CM, Narasimha S, WenRong X, Rahul R (2001) Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1α, 25-dihydroxyvitamin D3 receptor? Steroid 66:189–2001. doi:10.​1016/​S0039-128X(00)00134-3 CrossRef
12.
Zurück zum Zitat Arai H, Miyamoto K-I, Taketani Y et al (1997) A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japan women. J Bone Miner Res 12:915–921. doi:10.1359/jbmr.1997.12.6.915 PubMedCrossRef Arai H, Miyamoto K-I, Taketani Y et al (1997) A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japan women. J Bone Miner Res 12:915–921. doi:10.​1359/​jbmr.​1997.​12.​6.​915 PubMedCrossRef
13.
Zurück zum Zitat Schaid DJ, Rowland CM, Tines DE et al (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434. doi:10.1086/338688 PubMedCrossRef Schaid DJ, Rowland CM, Tines DE et al (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434. doi:10.​1086/​338688 PubMedCrossRef
18.
Zurück zum Zitat Gennari L, Becherini L, Mansani R et al (1999) FokI polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. J Bone Miner Res 14:1379–1386. doi:10.1359/jbmr.1999.14.8.1379 PubMedCrossRef Gennari L, Becherini L, Mansani R et al (1999) FokI polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. J Bone Miner Res 14:1379–1386. doi:10.​1359/​jbmr.​1999.​14.​8.​1379 PubMedCrossRef
20.
Zurück zum Zitat Zhang Y, Rosenberg L, Colton T et al (1996) Adult height and risk of breast cancer among white women in a case–control study. Am J Epidemiol 143:1123–1128PubMed Zhang Y, Rosenberg L, Colton T et al (1996) Adult height and risk of breast cancer among white women in a case–control study. Am J Epidemiol 143:1123–1128PubMed
Metadaten
Titel
Vitamin D receptor variants and breast cancer risk in the Polish population
verfasst von
P. Gapska
R. J. Scott
P. Serrano-Fernandez
T. Huzarski
T. Byrski
J. Kładny
J. Gronwald
B. Górski
C. Cybulski
J. Lubinski
T. Dębniak
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0107-1

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.